Tuesday, May 24, 2022

CRISPR CRITTERS

New CRISPR-combo boosts genome editing power in plants

UMD researchers develop the latest advances to CRISPR with a method to edit and regulate multiple genes simultaneously.

Peer-Reviewed Publication

UNIVERSITY OF MARYLAND

Poplar sprouts 

IMAGE: ON THE LEFT: POPLAR SPROUTS CONTAINING CRSPR-EDITED GENE. ON THE RIGHT, POPLAR SPROUTS WITH THE SAME CRSPR EDIT PLUS GENE ENHANCEMENTS TO IMPROVE GROWTH view more 

CREDIT: UMD

Ten years ago, a new technology called CRISPR-CAS9, made it possible for scientists to change the genetic code of living organisms. As revolutionary as it was, the tool had its limitations. Like the first cell phones that could only perform one function, the original CRISPR method can perform one function: removing or replacing genes in a genetic sequence. Later iterations of CRISPR were developed for another function that allowed scientists to change gene expression by turning them on or off, without removing them from the genome. But each of these functions could only be performed independently in plants.

Now, scientists from the University of Maryland College of Agriculture and Natural Resources, have developed CRISPR-Combo, a method to edit multiple genes in plants while simultaneously changing the expression of other genes. This new tool will enable genetic engineering combinations that work together to boost functionality and improve breeding of new crops.

“The possibilities are really limitless in terms of the traits that can be combined,” said Yiping Qi, an associate professor in the Department of Plant Science and Landscape Architecture and co-author of the study. “But what is really exciting is that CRISPR-Combo introduces a level of sophistication to genetic engineering in plants that we haven’t had before.”

The new research appears in the May, 2022, issue of the journal Nature Plants.

The benefits of manipulating more than one gene at a time can far outweigh the benefits of any one manipulation on its own. For example, imagine a blight raging through wheat fields, threatening farmer livelihoods and food security. If scientists could remove a gene from the wheat that makes it susceptible to the blight and simultaneously turn on genes that shorten the plant’s life cycle and increase seed production, they could rapidly produce blight-resistant wheat before the disease had the chance to do too much damage.

That’s the type of engineering Qi and his team demonstrated in four different phases of experimentation.

Step One: proving the concept:

Qi and his team had previously developed new CRISPR methods to regulate gene expression in plants, and to edit multiple genes at the same time. But to develop CRISPR-Combo, they had to establish that they could perform both of those genetic engineering functions in parallel without negative consequences. In this new paper, they demonstrated that using tomato and rice cells,. 

“As a proof of concept, we showed that we could knock out gene A and upregulate, or activate, gene B successfully, without accidentally crossing over and knocking out gene B or upregulating Gene A,” Qi said.

Then Qi and his colleagues tested CRISPR-Combo on a flowering plant called rockcress (ArabidopsisI), which is often used by researchers as a model for staple crops like corn and wheat. The researchers edited a gene that makes the plant more resistant to herbicides while activating a gene that causes early flowering, which produces seeds more quickly. The result was an herbicide-resistant rockcress plant that yielded eight generations in one year rather than the ordinary four.

More Efficient Engineering

For their third experiment, the team demonstrated how CRISPR-Combo could improve efficiency in plant breeding using tissue cultures from poplar trees. Breeding programs to develop new varieties of plants generally use tissue cultures rather than seeds—consider how a plant can regrow roots and leaves from a single stalk planted in the soil. Scientists genetically modify stem cells that have the ability to grow into full plants, and when those plants mature and produce seeds, the seeds will carry on the genetic modifications made to the stem cells.

Some plants are better at regenerating from tissue cultures than others, which makes this step the single largest bottleneck in genetic engineering of crops. For some plants the success rate is just 1%.

Qi and his team addressed the bottleneck by first editing a few traits in poplar cells, then activating three genes that promote plant tissue regeneration.    

“We showed in poplars that our new method could offer a solution to the tissue regeneration bottleneck, dramatically increasing the efficiency of genetic engineering,” Qi said.

Hormone-Free Short Cut

Currently, growing genetically engineered plants from tissue cultures requires the addition of growth hormones, which activate growth promoting genes. The research team shortcut this process in rice by directly activating these genes with CRISPR-Combo. The result was gene-edited rice from tissue cultures that did not require hormone supplementation. Qi and his colleagues found that tissue cultures grown with their method expressed more of the edited gene than tissue grown using hormones.

“This method results in a highly efficient genome editing process,” Qi said.

Now that the team has demonstrated their CRISPR-Combo method works in a variety of plants for multiple purposes, they intend to conduct experiments in citrus, carrots and potatoes to test its viability in a fruit, vegetable and staple crop. They are also working to create an herbicide resistant golden rice with enhanced nutritional content and red rice with increased antioxidants.

 

Other co-authors on the research paper from UMD include Associate Professor Gary Coleman, post-doctoral associates Changtian Pan and Gen Li, Post-doctoral scholar Filiz Gurel, graduate students Yanhao Cheng, Aimee A. Malzahn and Simon Sretenovic, Laboratory trainee and high school student Benjamin Leyson. 

This work was supported by NSF Plant Genome Research Program (award nos. IOS-1758745 and IOS-2029889), the USDA-NIFA (award nos. 2020-33522-32274 and 2019-67013-29197), the USDA-AFRI Agricultural Innovations Through Gene Editing Program (award no. 2021-67013-34554), Maryland Innovation Initiative Funding (award no. 1120-012_2), the USDA McIntire-Stennis project (award no. MD-PSLA-20006), NRT-INFEWS: UMD Global STEWARDS through the NSF National Research Traineeship Program (award no. 1828910) and the Foundation for Food and Agriculture Research. This story does not necessarily reflect the views of these organizations.

AS CORAL BLEACHING IS OCCURING

Scientists find sea corals are source of sought-after “anti-cancer” compound

Peer-Reviewed Publication

UNIVERSITY OF UTAH HEALTH

Eric W. Schmidt, Ph.D. 

IMAGE: ERIC W. SCHMIDT, PH.D., PROFESSOR, MEDICINAL CHEMISTRY, UNIVERSITY OF UTAH view more 

CREDIT: KRISTAN JACOBSEN FOR UNIVERSITY OF UTAH HEALTH

(Salt Lake City) - The bottom of the ocean is full of mysteries but scientists have recently uncovered one of its best-kept secrets. For 25 years, drug hunters have been searching for the source of a natural chemical that had shown promise in initial studies for treating cancer. Now, researchers at University of Utah Health report that easy-to-find soft corals—flexible corals that resemble underwater plants—make the elusive compound.

Identifying the source allowed the researchers to go a step further and find the animal’s DNA code for synthesizing the chemical. By following those instructions, they were able to carry out the first steps of re-creating the soft coral chemical in the laboratory.

“This is the first time we have been able to do this with any drug lead on Earth,” says Eric Schmidt, Ph.D., professor of medicinal chemistry at U of U Health. He led the study with Paul Scesa, Ph.D., postdoctoral scientist and first author, and Zhenjian Lin, Ph.D., assistant research professor.

The advance opens the possibility of producing the compound in the large amounts needed for rigorous testing and could one day result in a new tool to fight cancer.

A second research group led by Bradley Moore, Ph.D., from Scripps Institution of Oceanography at the University of California San Diego, independently showed that corals make related molecules. Both studies are published in the May 23 issue of Nature Chemical Biology.

A World of Possibilities

Soft corals have thousands of drug-like compounds that could work as anti-inflammatory agents, antibiotics, and more. But getting enough of these compounds has been a major barrier to developing them into drugs for clinical use. Schmidt says that these other compounds should also now be accessible using this new approach.

Corals aren’t the only animals that harbor potential therapeutics. Nature is crawling with snakes, spiders and other animals known to carry chemicals with healing properties. Yet that compounds from soft corals offer distinct advantages for drug development, Schmidt says.

Unlike venomous chemicals that are injected into prey, corals use their chemicals to ward off predators that try to eat them. Since they are made to be eaten, the soft coral chemicals are easily digestible. Similarly, drugs derived from these types of compounds should be able to be given as pills with a glass of water, rather than taken by injection or other more invasive means. “These compounds are harder to find but they’re easier to make in the lab and easier to take as medicine,” says Schmidt.

These possibilities had been just out of reach for decades. Getting to this point took the right know-how, and a little luck.

CAPTION

Soft corals make thousands of drug-like compounds that could work as anti-inflammatory agents, antibiotics, anti-cancer therapeutics, and more.

CREDIT

Bailey Miller


Hunting for the Source

Scesa found the long-sought-after compound in a common species of soft coral living off the Florida coast—just a mile from his brother’s apartment. In the 1990s, marine scientists reported that a rare coral near Australia carried a chemical, eleutherobin, with anti-cancer properties. The chemical disrupts the cytoskeleton, a key scaffold in cells, and soft corals use it as a defense against predators. But laboratory studies showed that the compound was also a potent inhibitor of cancer cell growth.

In the decades after, scientists searched but could not find the fabled “holy grail” chemical in the quantities needed for drug development and couldn’t remedy the problem without understanding how the chemical was made. Dogma had it that, similar to other kinds of marine life, the chemical was synthesized by symbiotic organisms that lived inside the animals.

“It didn’t make sense,” Scesa says. “We knew that corals must make eleutherobin.” After all, he and Schmidt reasoned, some soft coral species don’t have symbiotic organisms and yet their bodies contain the same class of chemicals.

Solving the mystery seemed a job made for Scesa. As a boy growing up in Florida, the ocean was his playground, and he spent countless hours exploring its depths and wildlife. In graduate school, he developed a penchant for organic chemistry and combined the two interests to better understand the chemical diversity of the seas.

Later, he joined the lab of natural products scientist Schmidt with a mission to track down the source of the drug lead. Scesa suspected coral species familiar to him might have the answer and brought small live samples from Florida to Utah, and the real hunt began.


CAPTION

Paul Scesa, Ph.D., dives for soft corals off the Florida coast. He studies the potential of soft coral chemicals as drug leads.

CREDIT

Paul Scesa


Decoding the Recipe

The next step was to find out whether the coral’s genetic code carried instructions for making the compound. Advances in DNA technology had recently made it possible to rapidly piece together the code of any species. The difficulty was, the scientists didn’t know what the instructions for making the chemical should look like. Imagine searching a cookbook for a certain recipe, only you don’t know what any of the words inside the book mean.

“It’s like going into the dark and looking for an answer where you don’t know the question,” remarks Schmidt.

They addressed the problem by finding regions of coral DNA that resembled genetic instructions for similar types of compounds from other species. After programming bacteria grown in the lab to follow coral DNA instructions specific to the soft coral, the microorganisms were able to replicate the first steps of making the potential cancer therapeutic.

This proved that soft corals are the source of eleutherobin. It also demonstrated that it should be possible to manufacture the compound in the lab. Their work is now focusing on filling in the missing steps of the compound’s recipe and determining the best way to produce large amounts of the potential drug.   

“My hope is to one day hand these to a doctor,” says Scesa. “I think of it as going from the bottom of the ocean to bench to bedside.”

# # #

The research was supported by the National Institutes of Health and the ALSAM Foundation and published in Nature Chemical Biology as “Ancient defensive terpene biosynthetic gene clusters in soft corals


CAPTION

Eric W. Schmidt, Ph.D., and Paul Scesa, Ph.D., of the University of Utah research marine natural products that could become drug leads.

CREDIT

Kristan Jacobsen for University of Utah Health


About University of Utah Health

University of Utah Health  provides leading-edge and compassionate care for a referral area that encompasses Idaho, Wyoming, Montana, and much of Nevada. A hub for health sciences research and education in the region, U of U Health has a $428 million research enterprise and trains the majority of Utah’s physicians and health care providers at its Colleges of Health, Nursing, and Pharmacy and Schools of Dentistry and Medicine. With more than 20,000 employees, the system includes 12 community clinics and five hospitals. U of U Health is recognized nationally as a transformative health care system and provider of world-class care.

Study reveals evidence that bacteria can live in snake and spider venoms

Newly published research led by Northumbria University shows that, contrary to what is commonly believed, the venom of snakes and spiders is actually populated with microbes, including bacteria that could cause infection in people who have suffered a bite

Peer-Reviewed Publication

NORTHUMBRIA UNIVERSITY

Dr Sterghios Moschos - Bacterial Adaptation to Venom in Snakes and Arachnida 

VIDEO: NEW RESEARCH SHOWS THAT CONTRARY TO COMMON BELIEF, VENOM IS NOT STERILE AND IS ACTUALLY FULL OF MICROBES. LEAD AUTHOR OF THE STUDY AND ASSOCIATE PROFESSOR IN CELLULAR AND MOLECULAR SCIENCES, DR STERGHIOS MOSCHOS, EXPLAINS WHAT THIS COULD POTENTIALLY MEAN FOR FUTURE TREATMENT. view more 

CREDIT: NORTHUMBRIA UNIVERSITY

Newly published research led by Northumbria University shows that, contrary to what is commonly believed, the venom of snakes and spiders is actually populated with microbes, including bacteria that could cause infection in people who have suffered a bite.

For decades scientists have thought that animal venom is an entirely sterile environment due to it being full of antimicrobial substances - materials that can kill bacteria.

However, new scientific evidence from research led by Northumbria University Associate Professor in Cellular and Molecular Sciences, Sterghios Moschos and venom biologist Steve Trim, Founder and CSO of biotechnology company Venomtech, has shown that this is not the case.

The work, published today in scientific journal Microbiology Spectrum demonstrates how adaptable microorganisms are. The study provides strong genetic and culture evidence that bacteria can not only survive in the venom glands of several species of snakes and spiders, but can also mutate to resist the notoriously toxic liquid that is venom.

The findings also suggest that victims of venomous animal bites may therefore also need to be treated for infections, not just antivenom to tackle the toxins deposited through the bite.

The publication of the study follows the news that Northumbria University’s research power continues to grow with results from the Research Excellence Framework (REF2021) showing Northumbria University with the biggest rise in research power ranking of any UK university. Its research power ranking rose to 23rd, having previously risen to 50thin 2014 from 80th in 2008, making Northumbria the sector’s largest riser in research power ranking for the second time.

 

Challenging the dogma of venom sterility

Seeking to address a gap in research, Dr Moschos and colleagues investigated the venom of five snake and two spider species. “We found that all venomous snakes and spiders that we tested had bacterial DNA in their venom,” explained Dr Moschos.

“Common diagnostic tools failed to identify these bacteria correctly - if you were infected with these, a doctor would end up giving you the wrong antibiotics, potentially making matters worse.

“When we sequenced their DNA we clearly identified the bacteria and discovered they had mutated to resist the venom. This is extraordinary because venom is like a cocktail of antibiotics, and it is so thick with them, you would have thought the bacteria would not stand a chance. Not only did they stand a chance, they had done it twice, using the same mechanisms,” added Dr Moschos.

“We also directly tested the resistance of Enterococcus faecalis, one of the species of bacteria we found in the venom of black-necked spitting cobras, to venom itself and compared it to a classic hospital isolate: the hospital isolate did not tolerate the venom at all, but our two isolates happily grew in the highest concentrations of venom we could throw at them.”

 

Implications for clinical treatment

2.7 million venomous bite-related injuries occur annually, predominantly across Africa, Asia and Latin America. Of these, it is thought that 75% of victims will develop infections in venom toxin-damaged tissue, with bacteria Enterococcus faecalis being a common cause of disease.

These infections have previously been thought to be a consequence of having an open wound from the bite, as opposed to the infection-causing bacteria having come from the venom itself.

The researchers say that their study shows the need for clinicians to consider treating snakebite victims not just for tissue destruction, but for infection too, as quickly as possible.

Steve Trim of Venomtech added: “By exploring the resistance mechanisms that help these bacteria survive, we can find entirely new ways of attacking multi-drug resistance, potentially through engineering antimicrobial venom peptides.”

Using Artificial Intelligence to Predict Life-Threatening Bacterial Disease in Dogs

UC Davis Veterinarians Develop AI Model for Accurate, Early Detection of Leptospirosis Infections

Peer-Reviewed Publication

UNIVERSITY OF CALIFORNIA - DAVIS

Dog Dialysis 

IMAGE: THE BACTERIAL DISEASE LEPTOSPIROSIS, IF NOT CAUGHT EARLY, CAN CAUSE KIDNEY FAILURE IN DOGS AMONG OTHER LIFE-THREATENING SYMPTOMS. view more 

CREDIT: UC VETERINARY MEDICAL CENTER - SAN DIEGO

Leptospirosis, a disease that dogs can get from drinking water contaminated with Leptospira bacteria, can cause kidney failure, liver disease and severe bleeding into the lungs. Early detection of the disease is crucial and may mean the difference between life and death.

Veterinarians and researchers at the University of California, Davis, School of Veterinary Medicine have discovered a technique to predict leptospirosis in dogs through the use of artificial intelligence. After many months of testing various models, the team has developed one that outperformed traditional testing methods and provided accurate early detection of the disease. The groundbreaking discovery was published in Journal of Veterinary Diagnostic Investigation.

“Traditional testing for Leptospira lacks sensitivity early in the disease process,” said lead author Krystle Reagan, a board-certified internal medicine specialist and assistant professor focusing on infectious diseases. “Detection also can take more than two weeks because of the need to demonstrate a rise in the level of antibodies in a blood sample. Our AI model eliminates those two roadblocks to a swift and accurate diagnosis.”

The research involved historical data of patients at the UC Davis Veterinary Medical Teaching Hospital that had been tested for leptospirosis. Routinely collected blood work from these 413 dogs was used to train an AI prediction model. Over the next year, the hospital treated an additional 53 dogs with suspected leptospirosis. The model correctly identified all nine dogs that were positive for leptospirosis (100% sensitivity). The model also correctly identified approximately 90% of the 44 dogs that were ultimately leptospirosis negative.

The goal for the model is for it to become an online resource for veterinarians to enter patient data and receive a timely prediction.

“AI-based, clinical decision making is going to be the future for many aspects of veterinary medicine,” said School of Veterinary Medicine Dean Mark Stetter. “I am thrilled to see UC Davis veterinarians and scientists leading that charge. We are committed to putting resources behind AI ventures and look forward to partnering with researchers, philanthropists, and industry to advance this science.”  

Detection model may help people

Leptospirosis is a life-threatening zoonotic disease, meaning it can transfer from animals to humans. As the disease is also difficult to diagnose in people, Reagan hopes the technology behind this groundbreaking detection model has translational ability into human medicine.

“My hope is this technology will be able to recognize cases of leptospirosis in near real time, giving clinicians and owners important information about the disease process and prognosis,” said Reagan. “As we move forward, we hope to apply AI methods to improve our ability to quickly diagnose other types of infections.”

Reagan is a founding member of the school’s Artificial Intelligence in Veterinary Medicine Interest Group comprising veterinarians promoting the use of AI in the profession. This research was done in collaboration with members of UC Davis’ Center for Data Science and Artificial Intelligence Research, led by professor of mathematics Thomas Strohmer. He and his students were involved in the algorithm building. The center strives to bring together world-renowned experts from many fields of study with top data science and AI researchers to advance data science foundations, methods, and applications.

Reagan’s group is actively pursuing AI for prediction of outcome for other types of infections, including a prediction model for antimicrobial resistant infections, which is a growing problem in veterinary and human medicine. Previously, the group developed an AI algorithm to predict Addison’s disease with an accuracy rate greater than 99%.

Other authors include Shaofeng Deng, Junda Sheng, Jamie Sebastian, Zhe Wang, Sara N. Huebner, Louise A. Wenke, Sarah R. Michalak and Jane E. Sykes. Funding support comes from the National Science Foundation.